Lrp4 Mediates Bone Homeostasis and Mechanotransduction through Interaction with Sclerostin In Vivo

Whitney A. Bullock, April M. Hoggatt, Daniel J. Horan, ..., Gabriela G. Loots, Fredrick M. Pavalko, Alexander G. Robling

HIGHLIGHTS
Missense mutation in the third beta-propeller of Lrp4 improve bone properties
The R1170W mutation in Lrp4 interferes with sclerostin inhibition in vivo
The R1170W Lrp4 mutation alters the bone wasting effects of mechanical disuse

Bullock et al., iScience 20, 205–215
October 25, 2019 © 2019 The Author(s).
https://doi.org/10.1016/j.isci.2019.09.023
Lrp4 Mediates Bone Homeostasis and Mechanotransduction through Interaction with Sclerostin In Vivo

Whitney A. Bullock,1 April M. Hoggatt,1 Daniel J. Horan,1 Andrew J. Elmendorf,1 Amy Y. Sato,1 Teresita Bellido,1 Gabriela G. Loots,2 Fredrick M. Pavalko,3,4 and Alexander G. Robling1,4,5,6,*

SUMMARY
Wnt signaling plays a key role in regulating bone remodeling. In vitro studies suggest that sclerostin’s inhibitory action on Lrp5 is facilitated by the membrane-associated receptor Lrp4. We generated an Lrp4 R1170W knockin mouse model (Lrp4 KI), based on a published mutation in patients with high bone mass (HBM). Lrp4 KI mice have an HBM phenotype (assessed radiographically), including increased bone strength and formation. Overexpression of a Sost transgene had osteopenic effects in Lrp4-WT but not Lrp4 KI mice. Conversely, sclerostin inhibition had blunted osteoanabolic effects in Lrp4 KI mice. In a disuse-induced bone wasting model, Lrp4 KI mice exhibit significantly less bone loss than wild-type (WT) mice. In summary, mice harboring the Lrp4-R1170W missense mutation recapitulate the human HBM phenotype, are less sensitive to altered sclerostin levels, and are protected from disuse-induced bone loss. Lrp4 is an attractive target for pharmacological targeting aimed at increasing bone mass and preventing bone loss due to disuse.

INTRODUCTION
Wnt signaling plays a key role in regulating bone modeling and remodeling. Perturbations in the Wnt pathway can have profound effects on bone properties, in both positive (osteosclerosis) and negative (osteopenia) directions. Those effects are most easily appreciated by the handful of skeletal conditions that are directly linked to mutations in the Wnt pathway. For example, patients with loss-of-function mutations in the Wnt co-receptor low-density lipoprotein receptor-related protein 5 (Lrp5) present with very low bone mass and density, a condition known as OsteoporosisPseudoglioma. Conversely, patients with gain-of-function mutations in LRPS can present with very high bone mass and density, a condition known as Endosteal Hyperostosis (Little et al., 2002; Boyden et al., 2002; Costantini et al., 2017; Van Wesenbeeck et al., 2003). The Lrp5 inhibitor sclerostin (Sost) is another key regulator of bone properties. Patients with homozygous loss-of-function mutations in Sost have sclerosteosis, characterized by dramatically increased bone mass and density (Balemans et al., 2001, 2002; Staehling-Hampton et al., 2002).

The skeletal phenotypes associated with mutations in the Wnt pathway, particularly the high-bone-mass causing mutations, have highlighted the potential utility of targeting Wnt pathway components for therapeutic benefit in patients with low bone mass. Specifically, the observation of increased bone mass in patients with sclerosteosis and the relatively restricted expression of Sost to bone tissue suggest that sclerostin targeting is an attractive strategy for improving bone properties. In both pre-clinical animal models and human clinical trials, treatment with antibodies raised against sclerostin has consistently improved bone properties beyond any currently approved therapies. At the time of this writing, the sclerostin monoclonal antibody Evenity was very recently approved in the United States and Japan for treatment of osteoporotic patients at high risk of fracture. A better understanding of sclerostin’s mechanism of action might reveal other targets or accessory agents that could make this approach safer, more efficacious, or more cost effective.

One of the more recent discoveries regarding sclerostin biology is the observation that sclerostin’s inhibitory action on Lrp5 is facilitated by the membrane-associated receptor Lrp4. Lrp4 is most widely studied for its role in the neuromuscular junction (NMJ), where it serves as a receptor for motor neuron-derived agrin/Wnt and facilitates acetylcholine receptor clustering on the myocyte. Loss of Lrp4 prevents the formation of NMJs and, consequently, leads to perinatal lethality (Barik et al., 2014). However, Lrp4 also plays...
a role in bone metabolism, and patients with certain NMJ-sparing missense mutations in LRP4 exhibit a sclerosteosis-like phenotype (SOST2; see Leupin et al., 2011). Deeper investigation revealed a sclerostin-interacting pocket in the central domain of the receptor’s third β-propeller (3βCD), mutation of which (e.g., R1170W, R1170Q, and W1186S) does not appear to alter the Agrin/LRP4/MuSK axis. However, these 3βCD mutations are proposed to impair interaction with sclerostin and, ultimately, sclerostin’s efficacy in inhibiting Lrp5/6. Accordingly, this domain of Lrp4 represents a potential opportunity to augment the sclerostin-Lrp5/6 interaction for therapeutic value (Chang et al., 2014).

In addition to regulating baseline bone mass and bone metabolism, the Wnt signaling pathway is critical for orchestrating the response of bone tissue to changes in the mechanical environment. Reduced mechanical input to bone (e.g., disuse) leads to decreases in bone mass and increased bone resorption. Conversely, increased mechanical stimulus to bone (e.g., loading) leads to increases in bone mass and osteogenesis. Sost/sclerostin plays a significant regulatory role in both of these phenomena (Tu et al., 2012; Lin et al., 2009), but it is unclear whether and how Lrp4 modifies sclerostin action in these processes.

In this communication, we further elucidate the interaction between Lrp4 and sclerostin using a new Lrp4 3βCD mutant mouse model (R1170W knockin). We examine the role of 3βCD in sclerostin efficacy by over-expressing or neutralizing sclerostin in Lrp4 R1170W mice using genetic and pharmacologic tools. We also probe the role of Lrp4 in disuse mechanotransduction, to evaluate its translational potential as bone-sparing therapy for disuse. Our results suggest that Lrp4 plays a significant role in bone metabolism and likely does so through interaction with sclerostin. Furthermore, Lrp4 might serve as a high-yield target for the development of compounds that can protect skeletal integrity during mechanodeprivation.

RESULTS
Mice with the Lrp4 R1170W Mutation Exhibit Increased Bone Mass
To better understand the cellular mechanisms driving the high bone mass (HBM) phenotype in patients with SOST2, we generated a mouse model recapitulating the mutation found in one of the families (LRP4 R1170W) using a CRISPR/Cas9 approach (Figure 1A). A C→T point mutation was knocked into the first position of the codon for aa1170 (confirmed by Sanger sequencing, Figure 1B), which resulted in the predicted Arg→Trp amino acid substitution. Western blotting for Lrp4 indicated that the missense mutation had no effect on Lrp4 protein expression in cortical bone (Figure 1C).
We next sought to determine whether the Lrp4-R1170W knockin mice (hereafter referred to as Lrp4KI) recapitulate the skeletal phenotype reported for patients with SOST2 with centrally located third β-propeller missense mutations (R1170W, R1170Q, W1186S). The Lrp4KI colony was expanded, along with wild-type (WT) and heterozygous (+/KI) littermates, and subjected to a battery of skeletal phenotyping endpoints. The mutation did not affect body mass or femur length (Figures 2B-2C), but Lrp4KI mice displayed significant increases in dual-energy X-ray absorptiometry (DEXA)-derived whole-body bone mineral density (BMD) and content (BMC) as early as 6 weeks of age (Figure 2A, Tables S1 and S2). At 18 weeks of age, μCT-derived femur and vertebral cortical and cancellous bone mass were significantly increased in Lrp4KI as compared with WT (+/+) and heterozygous (+/KI) littermates, despite (C) normal femur length. (E) The center panel depicts μCT reconstructions from the midshaft femur (upper), distal femur (middle) and vertebral body (lower) from representative +/+, +/KI, and KI/KI mice. Scale bar, 1 mm.

(H–J) Peripheral quantitative computed tomography (pQCT) measurements through the proximal tibia of 8-week-old female +/+, +/KI, and KI/KI mice reveal an increase in trabecular BMD and cortical BMC among KI/KI mice.

(K–M) Mechanical testing of femora from 18-week-old female +/+, +/KI, and KI/KI mice reveal increased ultimate force and energy to ultimate force (F_U) among knockin mice.

(N–P) Parietal thickness and planar area of foramen ovale in 18-week-old female +/+ and KI/KI female crania were not affected by the mutation. Male data are presented in Table S2. For (A) and (B), *p < 0.05 for comparison to +/+ by repeated measures ANOVA; for (C)–(P), *p < 0.05 for comparison to +/+ mice, using one-way ANOVA followed by Fisher’s protected least significant differences (PLSD) post hoc tests. n = 10/group. Data are presented as means ± SEM. See also Figure S1, Tables S1 and S2.

Figure 2. Lrp4KI Mice Have a High Bone Mass Phenotype

(A and B) (A) Whole-body bone mineral density (BMD) was significantly elevated in female Lrp4KI mice versus WT (+/+) and heterozygous (+/KI) littermates, despite (B) normal body mass.

(C–G) (D–G) Trabecular bone volume fraction (Tb. BV/TV) in the distal femur and fifth lumbar vertebra (L5) and cortical thickness (Ct. Th) in the mid-diaphyseal femur were significantly increased in 18-week-old female Lrp4KI mice compared with WT (+/+) and heterozygous (+/KI) littermates, despite (C) normal femur length. (E) The center panel depicts μCT reconstructions from the midshaft femur (upper), distal femur (middle) and vertebral body (lower) from representative +/+, +/KI, and KI/KI mice. Scale bar, 1 mm.

(H–J) Peripheral quantitative computed tomography (pQCT) measurements through the proximal tibia of 8-week-old female +/+, +/KI, and KI/KI mice reveal an increase in trabecular BMD and cortical BMC among KI/KI mice.

(K–M) Mechanical testing of femora from 18-week-old female +/+, +/KI, and KI/KI mice reveal increased ultimate force and energy to ultimate force (F_U) among knockin mice.

(N–P) Parietal thickness and planar area of foramen ovale in 18-week-old female +/+ and KI/KI female crania were not affected by the mutation. Male data are presented in Table S2. For (A) and (B), *p < 0.05 for comparison to +/+ by repeated measures ANOVA; for (C)–(P), *p < 0.05 for comparison to +/+ mice, using one-way ANOVA followed by Fisher’s protected least significant differences (PLSD) post hoc tests. n = 10/group. Data are presented as means ± SEM. See also Figure S1, Tables S1 and S2.
compared with both WT and heterozygous littermates (Figures 2D–2G and Tables S1 and S2). pQCT-derived cortical BMC and trabecular BMD in the proximal tibia of 8-week-old Lrp4KI mice were also significantly elevated (Figures 2H–2J). Three-point bending tests conducted on femora from 18-week-old mice revealed improved biomechanical properties in Lrp4KI mice, including significantly increased ultimate force and energy absorption (Figures 2K–2M).

Patients with SOST2 display calvarial sclerosis, which is recapitulated in Lrp4KI mice, although much more robustly in male mice (Table S2) compared with female mice (Figures 2N–2P). We previously reported stenosis of cranial nerve foramina in the basicranium of Lrp5-HBM and Sost knockout mouse models (Niziolek et al., 2015), which, at least in patients with sclerosteosis, can lead to cranial nerve deficits. However, the foramen ovale area was not significantly affected by the Lrp4KI mutation (Figure 2P). Although dental anomalies have not been reported in patients with SOST2, we also found dental anomalies in Lrp4KI mice, including supernumerary incisors and molars, with altered cusp morphology (Figure S1). In summary, Lrp4KI mice recapitulate the human HBM phenotype associated with SOST2.

**Lrp4KI Mice Have Increased Bone Formation, Sclerostin Expression, and Mildly Impaired Muscle Function**

Understanding of the mechanism of action (increased osteoanabolism or decreased osteocatabolism) for the observed HBM phenotype in Lrp4KI mice can guide translational applications for Lrp4 targeting. To investigate cellular activity, we performed quantitative cortical bone histomorphometry on Lrp4KI and WT control mice. Bone formation parameters were increased in 16- to 17-week-old but not 8- to 11-week-old mutant mice (Figures 3A–3G). No changes in the resorption marker CTx were detected in 8-week-old wild-type or Lrp4KI mice (Figure 4H). Taken together those observations suggest that the increase in bone mass observed in Lrp4KI mice is due to increased osteoblast-mediated bone formation, positioning Lrp4 as a target for anabolic action in bone.

Lrp4 has been proposed to serve as a sequestering protein for sclerostin, where it might serve as a molecular net to keep sclerostin levels high in the perimembrane region of bone cells (Fijalkowski et al., 2016). Serum levels of sclerostin were significantly greater in Lrp4KI mice than in WT and heterozygous mice (Figure 3I), which is consistent with patient data (Leupin et al., 2011) and supports the premise that mutant Lrp4 has an impaired ability to retain sclerostin at the cell surface. However, cortical bone tissue lysates from Lrp4KI mice yielded greater levels of sclerostin than lysates from WT mice (Figure 3H). That observation runs counter to the proposal that osteocytes with mutant Lrp4 are less efficient at retaining sclerostin locally, but it could also be explained by increased Sost expression in response to impaired Wnt inhibition (Taylor et al., 2018; Holdsworth et al., 2018).

Lrp4 is critical for NMJ formation and muscle function, where it serves as a receptor for motoneuron-derived Agrin, triggering interaction with MuSK (Shen et al., 2015). Mutations in the third β-propeller of Lrp4 can affect Agrin and MuSK binding (Ohkawara et al., 2014), so we performed in vivo muscle force testing in 10-week-old female WT and Lrp4KI mice (Figure 3J) to determine whether muscle function was affected by the R1170W missense mutation. Muscle mass, time to maximum torque, and half relaxation time were not different between WT and Lrp4KI mice, but maximum torque was significantly lower in Lrp4KI mice (Figures 3K–3M). However, a change in muscle function does not explain the HBM phenotype in Lrp4KI mice since the mutation was associated with reduced rather than enhanced muscle forces on the skeleton. In summary, Lrp4KI mice have HBM owing to increased anabolic activity, despite increased local and systemic sclerostin and compromised muscle function.

**Overexpression of Sost in Bone Tissue Causes Osteopenia in WT but Not Lrp4KI Mice**

Some reports suggest that Lrp4 acts as a facilitator of sclerostin inhibition of Lrp5/6, a proposition that is supported by direct interaction between the Lrp4 third β-propeller and sclerostin and by suppression of sclerostin-mediated Wnt inhibition by Lrp4 knockdown (Leupin et al., 2011). To determine whether compromise of the sclerostin-Lrp4 interaction can account for the HBM phenotype of Lrp4KI, we bred Lrp4KI mice to transgenic mice that overexpress human Sost in osteocytes (8kbDmp1-hSost). As expected, whole-body BMD and BMC were decreased in Lrp4 WT mice overexpressing Sost, but Lrp4KI mice were unaffected by Sost overexpression (Figures 4A and Tables S3 and S4). Lrp4KI mice were protected from the osteopenic effects of Sost overexpression in the cancellous compartment of both the femur and spine (Figures 4B–4D), but the protective effects in the cortical compartment could not be evaluated because Lrp4
WT mice did not manifest a Sost transgene effect when evaluated by μCT (Figure 4E) or bone formation parameters (Figures 4F and 4G). The Sost transgene had no effect on the resorption marker CTx in WT mice. CTx was slightly but significantly suppressed in Lrp4KI mice carrying the Sost transgene (Figure 4H).
In summary, the otherwise bone-suppressive effects of excessive sclerostin in bone were largely absent in Lrp4KI mice, suggesting that the R1170W mutation confers resistance to the inhibitory effects of sclerostin in vivo.

**Inactivation of Sclerostin Elicits a Blunted Osteogenic Effect in Lrp4KI Mice**

In the previous section we evaluated the ability of Lrp4KI mice to maintain high bone mass in the presence of excessive sclerostin. Next, we evaluated the contraposition regarding the sclerostin-Lrp4 interaction, i.e., whether Lrp4KI mice can elicit a full anabolic response when sclerostin is inactivated pharmacologically. If the R1170W mutation mimics a sclerostin-depleted environment, sclerostin neutralization should have minimal effects. Four weeks of treatment with sclerostin monoclonal antibody (Scl-mAb) increased whole-body BMD significantly compared with saline treatment in both WT and Lrp4KI female mice, but the antibody-induced BMD gain exhibited by Lrp4KI mice was only about half of that exhibited by WT mice (Figure 5E). Large gains in μCT-derived parameters (trabecular and cortical bone mass in the femur and spine) were measured among WT mice in response to Scl-mAb, but a blunted response (roughly a third to a half of WT gains, yet still significant) was observed in Lrp4KI mice (Figures 5A–5D). With the exception of mineral apposition rate (MAR), Scl-mAb treatment increased bone formation parameters significantly in WT mice but not in Lrp4KI mice (Figures 5F–5H, Table S5). In summary, the strong anabolic effects of sclerostin neutralization were compromised or absent in Lrp4KI mice, likely due to the mutation having similar functional (i.e., redundant) effects as sclerostin inactivation.
Lrp4KI Mice Are Partially Protected from Disuse-Induced Bone Wasting

Bone is a highly mechanosensitive tissue, and previous studies highlighted the importance of canonical Wnt signaling, particularly sclerostin, in this process. Mechanical disuse induces an increase in Sost expression, and Sost genetic deletion or sclerostin pharmacologic neutralization prevented disuse-induced bone loss (Robling et al., 2016). Given our accumulating evidence that the Lrp4 R1170W mutation confers properties to bone tissue that are similar to sclerostin neutralization, we explored the role of Lrp4KI in response to disuse mechanotransduction. Lrp4KI mice (12 weeks of age) were subjected to 4 weeks of unilateral mechanical disuse of the hindlimb using the Botulinum toxin-induced muscle paralysis model (Warner et al., 2006), and the degree of bone wasting was evaluated radiographically. The paralyzed limb of WT mice lost

Figure 5. Response to Pharmacologic Inhibition of Sost Is Blunted in Lrp4KI Mice

Cortical thickness (Ct.Th.) (A) and trabecular bone volume fraction (Tb BV/TV) (B) in the mid-diaphyseal and distal femur and fifth lumbar vertebra (L5) (C) were significantly increased in 16-week-old female Lrp4KI and WT (+/+ ) mice treated with sclerostin monoclonal antibody (Scl-mAb), but the gains were more pronounced in WT mice. (D) μCT reconstructions from the midshaft femur (upper) distal femur (middle) and vertebral body (lower) from representative +/+ and KI/KI mice treated with vehicle (–) or Scl-mAb (+). Scale bar, 1 mm. (E) Percent change in whole-body bone mineral density (BMD) during the 4-week antibody treatment period was greater in WT mice compared with Lrp4KI mice. (F–H) The periosteal bone formation parameters mineralizing surface (MS/BS), mineral apposition rate (MAR), and bone formation rate (BFR/BS) were significantly increased in WT but not Lrp4KI mice in response to sclerostin antibody. Scale bar 100 μm. For all data panels, data were tested using two-way ANOVA with Lrp4 genotype and the Scl-mAb injection as main effects. Inset at the top of each graph indicates significance of the main effects and interaction (# = Lrp4 genotype p < 0.05; @ = Scl-mAb p < 0.05; † = interaction p < 0.05). When at least one term was significant, Fisher’s PLSD post hoc tests were conducted and are indicated as *p < 0.05. For all panels, n = 6–10/group. Data are presented as means ± SEM. See also Table S5.

Lrp4KI Mice Are Partially Protected from Disuse-Induced Bone Wasting

Bone is a highly mechanosensitive tissue, and previous studies highlighted the importance of canonical Wnt signaling, particularly sclerostin, in this process. Mechanical disuse induces an increase in Sost expression, and Sost genetic deletion or sclerostin pharmacologic neutralization prevented disuse-induced bone loss (Robling et al., 2016). Given our accumulating evidence that the Lrp4 R1170W mutation confers properties to bone tissue that are similar to sclerostin neutralization, we explored the role of Lrp4KI in response to disuse mechanotransduction. Lrp4KI mice (12 weeks of age) were subjected to 4 weeks of unilateral mechanical disuse of the hindlimb using the Botulinum toxin-induced muscle paralysis model (Warner et al., 2006), and the degree of bone wasting was evaluated radiographically. The paralyzed limb of WT mice lost
~10% BMD, but Lrp4KI mice did not lose BMD in response to Botox (Figure 6A). However, although bone loss was spared in the paralyzed limb of Lrp4KI mice, we detected a significant failure to gain bone as was observed in the saline-treated limb of Lrp4KI mice (Figure 6A). Proximal tibial trabecular bone mass was significantly reduced by Botox in both WT and Lrp4KI mice, but the Lrp4KI mice lost roughly half as much bone as WT mice in response to paralysis (Figures 6B and 6D). Cortical bone loss was significant in Botox-treated WT mice as expected, but paralyzed (Botox-treated) limbs from Lrp4KI mice exhibited no difference from saline-treated limbs (Figure 6C). Periosteal bone formation was nearly abolished in the paralyzed limbs of WT mice, but Lrp4KI mice maintained unparalyzed levels of MAR but not MS/BS or BFR (Table S6). In summary, Lrp4KI mice exhibit less severe bone wasting in response to mechanical disuse...
than WT mice, suggesting that pharmacologically targeting the third β-propeller of Lrp4 during a disuse event might have therapeutic value in reducing bone loss.

**DISCUSSION**

High bone mass (HBM)-causing mutations in genes coding for secreted or plasma membrane-bound Wnt signaling components represent rare glimpses into molecular targeting opportunities to improve bone health and fracture resistance in osteoporotic patients. Targets that can be modulated to produce anabolic action in the skeleton are particularly attractive, given the paucity of approved and pipeline osteoanabolic agents. The identification of patients with a sclerosteosis-like condition harboring missense mutations in LRP4 (Leupin et al., 2011) has furthered our understanding of accessory proteins involved in extracellular Wnt inhibition and also provided additional avenues for therapeutic development. We engineered an orthologous mouse model to one of the HBM human families identified with an HBM-causing LRP4 missense mutation, which yielded an HBM phenotype and provided a tool to study more mechanistic questions beyond those suited to clinical studies (e.g., bone strength, tissue protein levels). We found that the Lrp4 R1170W knockin mice recapitulate the skeletal phenotype observed in patients with SOST2 and that the phenotype is driven largely by anabolic action.

Moreover, we were able to identify several additional traits associated with Lrp4 3βCD mutation that have not been reported in patients with SOST2, including changes to the dentition (also observed in other Lrp4 models [Ahn et al., 2017]), compromised muscle function, and increased levels of sclerostin in osteocyte-enriched protein lysates from bone tissue. Conversely, we failed to find some traits in the murine model that have been identified in patients (e.g., skull thickness, phenotype in the heterozygous state). The reduction in muscle function in Lrp4KI mice is surprising. Certain missense mutations in the third β-propeller of LRp4 (e.g., E1233K and R1277H) can cause congenital myasthenic syndrome (CMS), a non-autoimmune disorder associated with progressive muscle weakness. CMS mutations located on the outer edge of the third β-propeller impair Lrp4 interaction with both Agrin and MuSK—key interactions for NMJ assembly and maintenance (Ohkawara et al., 2014). However, cell culture models show that overexpression of R1170W impairs Wnt signaling but has no effect on Agrin-induced MuSK signaling, suggesting that centrally located missense mutations (e.g., R1170W) affect Wnt but not Agrin/MuSK, whereas those located on the propeller edge have the inverse effect. Our data do not identify a direct role for the R1170W mutation in regulating muscle function; other indirect explanations (e.g., R1170W-induced increase in circulating sclerostin might impair muscle function) cannot be ruled out.

Another interesting finding was the increased levels of sclerostin protein in bone extracts. Human patients with LRP4 HBM (Fijalkowski et al., 2016), other mouse models of Lrp4 mutation (Xiong et al., 2015; Boudin et al., 2017), and WT mice treated with Lrp4 neutralizing antibody (Chang et al., 2014) all have increased levels of circulating sclerostin, which we confirmed in our R1170W model. Additionally, we also found increased sclerostin protein in bone, which was surprising given (1) Lrp4’s purported role in retaining sclerostin at high levels in the local bone environment (which is presumably inhibited by the Lrp4 HBM mutations) and (2) previous reports of decreased sclerostin in the osteocytes of Lrp4 knockin mice (R1170Q), as assessed by immunohistochemistry (Boudin et al., 2017). One explanation for the increase in tissue sclerostin despite a lack of its primary retention mechanism (functional Lrp4) that is consistent with our previous data is the self-regulation of sclerostin expression observed when sclerostin signaling is inhibited genetically or pharmacologically (Witcher et al., 2018).

Investigation of the interaction between Lrp4 and sclerostin has thus far been restricted to cell culture experiments involving overexpression of various signaling components, which have the potential to be problematic or misleading specifically in Wnt-related in vitro studies (Goel et al., 2012). We designed in vivo experiments to better understand this interaction in a more physiologic context and did so using excessive (hSost transgene) and depleted (Scl-Ab) sclerostin levels in Lrp4KI mice. Lrp4KI mice were largely immune to changes in levels of sclerostin, where Lrp4KI mice overexpressing Sost failed to manifest the osteopoenic effects of the transgene and antibody-treated Lrp4KI failed to gain as much bone as treated WT mice (although they did exhibit significant gains for several parameters). Although those experiments do not prove a direct role in binding alterations, they do suggest that Lrp4 3βCD mutations disturb the normal function of sclerostin in regulating bone mass in an in vivo context, both positively and negatively.
To provide a translational context to Lrp4 clinical utility, we explored the role of Lrp4 in mediating disuse osteoporosis. Wnt is a major regulator of mechanical signaling in bone, and we have previously reported therapeutic effects of modulating Lrp5, Sost, and β-catenin in mechanical models (Niziolek et al., 2015; Robling et al., 2016, Bullock et al., 2019). Here, we evaluated the utility of Lrp4 modulation in a muscle paralysis model of bone loss. Lrp4<sup>−/−</sup> mice exhibited significant protection from the bone wasting effects of lower limb paralysis, suggesting that pharmacologic targeting of Lrp4 during or soon after a disuse injury might have clinical benefit.

Recent regulatory approval for clinical use of sclerostin-neutralizing antibody in several countries (United States, Japan, Canada, South Korea, Australia) has opened the door for widespread use of the first Wnt-based therapy for bone health. Whether other components (e.g., Lrp4) alone or in conjunction with sclerostin targeting can provide additional benefits to patients remains to be determined, but Lrp4 targeting for low bone mass states appears attractive from a preclinical perspective.

Limitations of the Study

The experiments performed have several limitations. First, the R1170W mutation was expressed globally. Although that approach provided an orthologous model of the human patients with HBM-causing LRP4 mutations, it did not allow for cell-selective Lrp4 impairment as could be achieved with a conditional knockin approach (Cui et al., 2011). Therefore, we do not know the cell type in which Lrp4 is most critical for regulating sclerostin signaling. Second, we did not perform assays to assess sclerostin-Lrp4 interaction in vivo, with and without the R1170W mutation. Those experiments have been performed in overexpression studies <em>in vitro</em>, but it is possible that, in the context of the <em>in vivo</em> environment, the interaction is modified. Lastly, the Lrp4 mutant mice had altered Lrp4 function since conception. For translational purposes, it would be more appropriate to understand the acute effects of disrupting the Lrp4-sclerostin axis, as could be accomplished with neutralizing antibody or a small molecule inhibitor (Chang et al., 2014).

METHODS

All methods can be found in the accompanying Transparent Methods supplemental file.

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2019.09.023.

ACKNOWLEDGMENTS

Thanks to Emily Pemberton for assistance with colony maintenance. Thank you to Amgen/UCB Pharma for providing sclerostin antibody. This work was supported by NIH grants AR070624 (to W.A.B.), AR065971 (to W.A.B.), AR069029 (to F.M.P.), DK075730 (to G.G.L.) and AR053237 (to A.G.R.); and by VA grants BX001478 and BX003783 (to A.G.R.). G.G.L. performed work under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344. This publication was made possible, in part, with support from the Indiana Clinical and Translational Sciences Institute funded, in part by Award Number UL1TR002529 from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

AUTHOR CONTRIBUTIONS

W.A.B. designed and performed experiments. A.M.H., D.J.H., A.J.E., and A.Y.S. – data collection. T.B., G.G.L., and F.M.P. designed experiments. A.G.R. designed experiments and is the Lead Contact.

DECLARATION OF INTERESTS

The authors declare no competing financial interests.

Received: April 11, 2019
Revised: August 6, 2019
Accepted: September 13, 2019
Published: October 25, 2019
REFERENCES

Ahn, Y., Sims, C., Murray, M.J., Kuhlmann, P.K., Fuentes-Antras, J., Weatherbee, S.D., and Krumlauf, R. (2017). Multiple modes of Lrp4 function in modulation of Wnt/beta-catenin signaling during tooth development. Development 144, 2824–2836.

Balemans, W., Ebeling, M., Patel, N., Van Hul, E., Olson, P., Dioszegi, M., Laczka, C., Wuyts, W., Van Den Ende, J., Willems, P., et al. (2001). Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 10, 537–543.

Balemans, W., Patel, N., Ebeling, M., Van Hul, E., Wuyts, W., Laczka, C., Dioszegi, M., Dikkers, F.G., Hildering, P., Willems, P.J., et al. (2002). Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 39, 1–97.

Barik, A., Zhang, B., Sohal, G.S., Xiong, W.C., and Mei, L. (2014). Crosstalk between Agrin and Wnt signaling pathways in development of vertebrate neuromuscular junction. Dev. Neurobiol. 74, 828–838.

Boudin, E., Yorgun, T., Fijalkowski, I., Sonntag, S., Steenackers, E., Hendrickx, G., Peeters, S., Mare, A., Vervaet, B., Verhulst, A., et al. (2017). The Lrp4 R117Q homozygous knock-in mouse recapitulates the bone phenotype of sclerosteosis in humans. J. Bone Miner. Res. 32, 1739–1749.

Boyden, L.M., Mao, J., Mitzner, L., Feist, A., Mitnick, M.A., Wu, D., Insogna, K., and Belfield, J.I. (2002). High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 346, 1513–1521.

Bullock, W.A., Hoggatt, A., Horan, D.J., Yokota, H., Sebastian, A., Loots, G.G., Pavao, F.M., and Robling, A.G. (2019). Expression of a degradation-resistant beta-catenin mutant in osteocytes protects the skeleton from mechanodeprivation-induced bone wasting. J. Bone Miner. Res. https://doi.org/10.1002/jbmr.3812.

Chang, M.K., Kramer, J., Huber, T., Kinzel, B., Guth-Gundel, S., Leupin, O., and Kneissel, M. (2014). Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels. Proc. Natl. Acad. Sci. U S A 111, E5187–E5195.

Costantini, A., Kekalainen, P., Makite, R.E., and Makite, O. (2017). High bone mass due to novel LRPS and AMER1 mutations. Eur. J. Med. Genet. 60, 675–679.

Cui, Y., Niziolek, P.J., Macdonald, B.T., Zylstra, C.R., Alemina, N., Robinson, D.R., Zhong, Z., Matthes, S., Jacobsen, C.M., Conlon, R.A., et al. (2011). Lrp5 functions in bone to regulate bone mass. Nat. Med. 17, 684–691.

Fijalkowski, I., Geets, E., Steenackers, E., Van Hoof, V., Ramos, F.J., Mortier, G., Fortuna, A.M., Van Hul, W., and Boudin, E. (2016). A novel domain-specific mutation in a sclerosteosis patient suggests a role of LRPS as an anchor for sclerostin in human bone. J. Bone Miner. Res. 31, 874–881.

Goel, S., Chin, E.N., Fakhraldeen, S.A., Berry, S.M., Beebe, D.J., and Alexander, C.M. (2012). Both LRPS and LRPE6 receptors are required to respond to physiological Wnt ligands in mammalian epithelial cells and fibroblasts. J. Biol. Chem. 287, 16454–16466.

Holdsworth, G., Greenslade, K., Jose, J., Stencel, Z., Kirby, H., Moore, A., Ke, H.Z., and Robinson, M.K. (2018). Dampening of the bone formation response following repeat dosing with sclerostin antibody in mice is associated with up-regulation of Wnt antagonists. Bone 107, 93–103.

Leupin, O., Peters, E., Halleux, C., Hu, S., Kramer, J., Morvan, F., Brousmeester, T., Schirle, M., Bueno-Lozano, M., Fuentes, F.J., et al. (2011). Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J. Biol. Chem. 286, 19489–19500.

Lin, C., Jiang, X., Dai, Z., Guo, X., Weng, T., Wang, J., Li, Y., Feng, G., Gao, X., and He, L. (2009). Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J. Bone Miner. Res. 24, 1651–1661.

Little, R.D., Carulli, J.P., Del Mastro, R.G., Dupuis, J., Osborne, M., Folz, C., Manning, S.P., Swain, P.M., Zhao, S.C., et al. (2002). A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 70, 11–19.

Niziolek, P.J., Bullock, W., Warman, M.L., and Robling, A.G. (2011). Missense mutations in LRPS associated with high bone mass protect the mouse skeleton from disuse- and ovariectomy-induced Osteopenia. PLoS One 6, e140775.

Ohkawara, B., Cabrera-Serrano, M., Nakata, T., Milone, M., Asai, N., Ito, K., Ito, M., Masuda, A., Ito, Y., Engel, A.G., and Ohno, K. (2014). LRPS third beta-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner. Hum. Mol. Genet. 23, 1856–1868.

Robling, A.G., Kang, K.S., Bullock, W.A., Foster, W.H., Murugesh, D., Loots, G.G., and Genetos, D.C. (2016). Sost, independent of the non-coding enhancer ECS5, is required for bone mechnoadaptation. Bone 92, 180–188.

Shen, C., Xiong, W.C., and Mei, L. (2015). LRPS4 in neuromuscular junction and bone development and diseases. Bone 80, 101–108.

Staehling-Hampton, K., Proli, S., Paepere, B.W., Zhao, L., Charmley, P., Brown, A., Gardner, J.C., Galas, D., Schatzman, R.C., Beighton, P., et al. (2002). A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am. J. Med. Genet. 110, 144–152.

Taylor, S., Hu, R., Pacheco, E., Luecher, K., Pyrah, I., Ominsky, M.S., and Boyce, R.W. (2018). Differential time-dependent transcriptional changes in the osteoblast lineage in cortical bone associated with sclerostin antibody treatment in ovariectomized rats. Bone Rep. 8, 95–103.

Tu, X., Rhee, Y., Condon, K.W., Bivi, N., Allen, M.R., Dwyer, D., Stolina, M., Turner, C.H., Robling, A.G., Plotkin, L.I., and Belido, T. (2012). Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone 50, 209–217.

Van Wesenbeeck, L., Cleren, E., Gram, J., Beals, R.K., Benichou, O., Scopelliti, D., Key, L., Renton, T., Bartels, C., Gong, Y., et al. (2006). Three novel missense mutations in the LDL receptor-related protein 5 (LRPS) gene in different conditions with an increased bone density. Am. J. Hum. Genet. 72, 763–771.

Warner, S.E., Sanford, D.A., Becker, B.A., Bain, S.D., Srivivasan, S., and Gross, T.S. (2006). Botox induced muscle paralysis rapidly degrades bone. Bone 38, 257–264.

Witcher, P.C., Miner, S.E., Horan, D.J., Bullock, W.A., Lim, K.E., Kang, K.S., Adaniya, A.L., Ross, R.D., Loots, G.G., and Robling, A.G. (2018). Sclerostin neutralization unleashes the osteanabolic effects of Dkk1 inhibition. JCI Insight 3, https://doi.org/10.1172/jci.insight.98673.

Xiong, L., Jung, J.U., Wu, H., Xia, W.F., Pan, J.X., Shen, C., Mei, L., and Xiong, W.C. (2015). LRPS4 in osteoblasts suppresses bone formation and promotes osteoestrogen and bone resorption. Proc. Natl. Acad. Sci. U S A 112, 3487–3492.

iScience 20, 205–215, October 25, 2019 215

iScience
Supplemental Information

Lrp4 Mediates Bone Homeostasis and Mechanotransduction through Interaction with Sclerostin In Vivo

Whitney A. Bullock, April M. Hoggatt, Daniel J. Horan, Andrew J. Elmendorf, Amy Y. Sato, Teresita Bellido, Gabriela G. Loots, Fredrick M. Pavalko, and Alexander G. Robling
Figure S1. Lrp4KI mice display supernumerary teeth and altered molar cusp patterns. Related to Figure 2. (A) µCT reconstructions from the occlusal view of the maxillary incisors illustrating a set of secondary incisors (blue arrow) distolingual to the primary set in WT (+/+ and Lrp4KI (KI/KI) mice. (B and C) Close-up view of the mandibular dentition reveal extra incisors of varying development, and additional molar teeth on the distal end and lingual edge of the tooth row (blue arrows). The molars also exhibit altered cusp pattern compared to those seen in the WT mice.
Table S1. Radiographic and biomechanical analysis of female Lrp4 WT, HET and KI mice. Related to Figure 2.

|                           | Wild-type (WT) | R1170W/+ (HET) | R1170W/R1170W (KI) |
|---------------------------|----------------|----------------|--------------------|
| Whole Body BMC (18 wk; g) | 0.49 ± 0.1     | 0.47 ± 0.1     | 0.77 ± 0.1         |
| Body Weight (18 wk; g)    | 22.5 ± 1.3     | 22.1 ± 1.0     | 21.6 ± 2.2         |
| Femur length (mm)         | 15.2 ± 0.5     | 15.0 ± 0.2     | 15.3 ± 0.5         |

**Femur µCT**

|                          | Wild-type (WT) | R1170W/+ (HET) | R1170W/R1170W (KI) |
|--------------------------|----------------|----------------|--------------------|
| Tb.N (1/mm)              | 2.16 ± 0.35    | 1.88 ± 0.30 *  | 2.84 ± 0.29 *      |
| Tb.Th (mm)               | 0.04 ± 0.01    | 0.04 ± 0.01    | 0.08 ± 0.01 *      |
| Tb.Sp (mm)               | 0.47 ± 0.08    | 0.55 ± 0.09 *  | 0.34 ± 0.05 *      |
| Tb.BMD (mg/cm³)          | 868 ± 40       | 879 ± 37       | 924 ± 34 *         |
| Tb.BMC (mg)              | 0.06 ± 0.12    | 0.02 ± 0.01    | 0.41 ± 0.18 *      |
| Ct.BMD (mg/cm³)          | 1.08 ± 0.02    | 1.08 ± 0.01    | 1.09 ± 0.01 *      |
| Ct.BMC (mg)              | 2.59 ± 0.42    | 2.60 ± 0.09    | 3.97 ± 0.70 *      |

**5th Lumbar µCT**

|                          | Wild-type (WT) | R1170W/+ (HET) | R1170W/R1170W (KI) |
|--------------------------|----------------|----------------|--------------------|
| Tb.N (1/mm)              | 3.79 ± 0.8     | 3.69 ± 1.0     | 5.93 ± 1.1 *       |
| Tb.Th (mm)               | 0.05 ± 0.01    | 0.05 ± 0.01    | 0.08 ± 0.02 *      |
| Tb.Sp (mm)               | 0.26 ± 0.04    | 0.27 ± 0.05    | 0.17 ± 0.05 *      |
| Tb.BMD (mg/cm³)          | 871 ± 10       | 878 ± 15       | 871 ± 19           |
| Tb.BMC (mg)              | 0.28 ± 0.19    | 0.26 ± 0.14    | 0.79 ± 0.27 *      |

**Femur 3 point bending**

|                          | Wild-type (WT) | R1170W/+ (HET) | R1170W/R1170W (KI) |
|--------------------------|----------------|----------------|--------------------|
| Stiffness (N/mm)         | 70.2 ± 12.2    | 67.9 ± 21.9    | 108.6 ± 2.6 *      |
| Energy to F_U (mJ)       | 3.38 ± 1.3     | 4.10 ± 1.3     | 9.35 ± 1.6 *       |
| Energy to F_F (mJ)       | 10.1 ± 2.6     | 9.6 ± 2.9      | 15.3 ± 4.7 *       |

*p<0.05 for comparison to WT mice, using one-way ANOVA followed by Fisher’s PLSD post hoc tests.
Table S2. Radiographic and biomechanical analysis of male Lrp4 WT, HET and KI mice. Related to Figure 2.

|                                | Wild-type (WT) | R1170W/+ (HET) | R1170W/R1170W (KI) |
|--------------------------------|----------------|----------------|--------------------|
| Whole Body BMD (18 wk; g/cm²)  | 70.1 ± 7.3     | 75.0 ± 8.0     | 91.6 ± 12.6*       |
| Whole Body BMC (18 wk; g)      | 0.54 ± 0.1     | 0.57 ± 0.1     | 0.76 ± 0.2*        |
| Body Weight (18 wk; g)         | 28.3 ± 0.8     | 27.6 ± 3.2     | 26.3 ± 2.2         |
| Femur length (mm)              | 15.4 ± 0.5     | 15.1 ± 0.2     | 15.2 ± 0.2         |

**Femur µCT**

|                                |                |                |                    |
|--------------------------------|----------------|----------------|--------------------|
| Tb.BV/TV (unitless)            | 0.046 ± 0.02   | 0.046 ± 0.02   | 0.166 ± 0.05*      |
| Tb.N (1/mm)                    | 3.193 ± 0.34   | 2.960 ± 0.27   | 3.722 ± 0.31*      |
| Tb.Th (mm)                     | 0.05 ± 0.00    | 0.05 ± 0.01    | 0.07 ± 0.01*       |
| Tb.Sp (mm)                     | 0.31 ± 0.03    | 0.34 ± 0.03    | 0.25 ± 0.03*       |
| Tb.BMD (mg/cm³)                | 887.3 ± 8.7    | 887.1 ± 21.6   | 901.5 ± 15.0*      |
| Tb.BMC (mg)                    | 0.16 ± 0.10    | 0.17 ± 0.08    | 0.67 ± 0.23*       |
| Ct.BMD (mg/cm³)                | 1.06 ± 0.01    | 1.06 ± 0.00    | 1.07 ± 0.01*       |
| Ct.BMC (mg)                    | 2.43 ± 0.23    | 2.57 ± 0.21    | 3.79 ± 0.28*       |
| Ct.Th (mm)                     | 0.188 ± 0.01   | 0.195 ± 0.01   | 0.259 ± 0.02*      |

**5th Lumbar µCT**

|                                |                |                |                    |
|--------------------------------|----------------|----------------|--------------------|
| Tb.BV/TV (unitless)            | 0.20 ± 0.03    | 0.18 ± 0.03    | 0.37 ± 0.15*       |
| Tb.N (1/mm)                    | 4.75 ± 0.22    | 4.45 ± 0.23*   | 5.63 ± 1.15*       |
| Tb.Th (mm)                     | 0.47 ± 0.01    | 0.048 ± 0.00   | 0.06 ± 0.02*       |
| Tb.Sp (mm)                     | 0.20 ± 0.01    | 0.21 ± 0.013*  | 0.18 ± 0.06*       |
| Tb.BMD (mg/cm³)                | 881.7 ± 6.3    | 882.5 ± 9.5    | 870.9 ± 23.5       |
| Tb.BMC (mg)                    | 0.342 ± 0.07   | 0.289 ± 0.07   | 0.586 ± 0.24*      |

**Femur 3 point bending**

|                                |                |                |                    |
|--------------------------------|----------------|----------------|--------------------|
| Ultimate Force (N)             | 15.7 ± 2.9     | 16.9 ± 2.7     | 32.2 ± 4.4*        |
| Stiffness (N/mm)               | 56.9 ± 18.7    | 79.9 ± 20.8*   | 102.7 ± 51.2*      |
| Energy to FU (mJ)              | 4.94 ± 1.5     | 4.92 ± 1.2     | 11.96 ± 3.7*       |
| Energy to FF (mJ)              | 8.2 ± 2.8      | 11.7 ± 3.0*    | 16.6 ± 3.5 *       |

**Cranial Dimensions**

|                                |                |                |                    |
|--------------------------------|----------------|----------------|--------------------|
| Skull Thickness (µm)            | 0.201 ± 0.08   | ----           | 0.295 ± 0.05 *     |
| Foramen Ovale Area (µm)        | 0.337 ± 0.18   | ----           | 0.273 ± 0.11       |

*p<0.05 for comparison to WT mice, using one-way ANOVA followed by Fisher’s PLSD post hoc tests.
Table S3. Radiographic analysis and serum measurements in WT and Lrp4-KI female mice with and without a Dmp1-hSost transgene. Related to Figure 4.

|                        | WT / NTG | WT / Dmp1-hSost | KI / NTG | KI / Dmp1-hSost |
|------------------------|----------|-----------------|----------|-----------------|
| Whole Body BMC (17 wk; g) | 0.473 ± 0.02 | 0.446 ± 0.04*   | 0.610 ± .07 | 0.639 ± 0.09    |

**Femur µCT**

|                        | WT / NTG | WT / Dmp1-hSost | KI / NTG | KI / Dmp1-hSost |
|------------------------|----------|-----------------|----------|-----------------|
| Tb.N (1/mm)#@          | 2.11 ± 0.36 | 1.24 ± 0.46*   | 2.42 ± 0.39 | 1.99 ± 0.48    |
| Tb.Th (mm)#            | 0.038 ± 0.006 | 0.046 ± 0.013 | 0.067 ±0.010 | 0.063 ± 0.014  |
| Tb.Sp (mm)#@†          | 0.49 ± 0.10 | 0.88 ± 0.26*   | 0.41 ± 0.07 | 0.53 ± 0.15    |
| Tb.BMD (mg/cm³)#       | 923.7 ± 24.6 | 926.1 ± 31.7   | 948.9 ± 20.1 | 939.3 ± 18.2   |
| Tb.BMC (mg)#@          | 0.05 ± 0.02 | 0.01 ± 0.01*   | 0.28 ± 0.14 | 0.17 ± 0.11    |
| Ct.BMD (mg/cm³)#       | 1.07 ± 0.01 | 1.06 ± 0.02    | 1.09 ± 0.02 | 1.08 ± 0.02    |
| Ct.BMC (mg)#           | 2.44 ± 0.14 | 2.35 ± 0.14    | 3.56 ± 0.34 | 3.54 ± 0.46    |

**5th Lumbar µCT**

|                        | WT / NTG | WT / Dmp1-hSost | KI / NTG | KI / Dmp1-hSost |
|------------------------|----------|-----------------|----------|-----------------|
| Tb.N (1/mm)#           | 3.72 ± 0.2 | 2.41 ± 0.8     | 5.41 ± 2.5 | 5.13 ± 1.2     |
| Tb.Th (mm)#            | 0.048 ± 0.003 | 0.056 ± 0.007 | 0.083 ± 0.011 | 0.085 ± 0.021 |
| Tb.Sp (mm)#@          | 0.263 ± 0.16 | 0.440 ± 0.12*  | 0.254 ± 0.23 | 0.204 ± 0.06   |
| Tb.BMD (mg/cm³)#       | 849.6 ± 14.1 | 863.1 ± 29.0   | 875.5 ± 3.83 | 877.9 ± 23.6   |
| Tb.BMC (mg)#           | 0.237 ± 0.02 | 0.133 ± 0.06   | 0.617 ± 0.36 | 0.703 ± 0.27   |
| Serum sclerostin (pg/µL)# | 148.3 ± 19 | 131.2 ± 32     | 700.3 ± 291 | 778.8 ± 335    |

Symbols indicate significance of the main effects and interaction (#=Lrp4 genotype p<0.05; @=Dmp1-hSost p<0.05; †=interaction p<0.05). When at least one term was significant, Fisher’s PLSD post-hoc tests were conducted and are indicated as *p<0.05.
Table S4. Radiographic analysis and serum measurements in WT and Lrp4-KI male mice with and without a Dmp1-hSost transgene. Related to Figure 4.

|                          | WT / NTG       | WT / Dmp1-hSost | KI / NTG       | KI / Dmp1-hSost |
|--------------------------|----------------|-----------------|----------------|-----------------|
| Whole Body BMC (17 wk; g) | 0.55 ± 0.10    | 0.55 ± 0.10     | 0.68 ± 0.08    | 0.72 ± 0.13     |
| Whole Body BMD (17 wk; g/cm²) | 72.3 ± 8.6    | 73.2 ± 8.6      | 85.1 ± 7.3     | 89.9 ± 10.2     |
| **Femur µCT**            |                |                 |                |                 |
| Tb.BV/TV (unitless)*      | 0.08 ±0.04     | 0.05 ± 0.02*    | 0.12 ± 0.03    | 0.17 ± 0.04*    |
| Tb.N (1/mm)†              | 3.34 ± 0.68    | 1.98 ± 0.25*    | 3.32 ± 0.27    | 3.56 ± 0.32     |
| Tb.Th (mm)‡               | 0.050 ± 0.01   | 0.058 ± 0.01*   | 0.067 ± 0.00   | 0.072 ± 0.00    |
| Tb.Sp (mm)‡               | 0.307 ± 0.06   | 0.514 ± 0.06*   | 0.287 ± 0.03   | 0.266 ± 0.03    |
| Tb.BMD (mg/cm³)†          | 916.5 ± 19.6   | 925.0 ± 19.1*   | 925.9 ± 9.8    | 936.1 ± 14.7*   |
| Tb.BMC (mg)†              | 0.345 ± 0.19   | 0.184 ± 0.10    | 0.471 ± 0.13   | 0.793 ± 0.32*   |
| Ct.BMD (mg/cm³)§          | 1.05 ± 0.03    | 1.04 ± 0.03     | 1.07 ± 0.01    | 1.08 ± 0.02     |
| Ct.BMC (mg)§              | 2.58 ± 0.51    | 2.53 ± 0.19     | 3.47 ± 0.17    | 3.84 ± 0.47     |
| Ct.Th (mm)§               | 0.198 ± 0.03   | 0.198 ± 0.01    | 0.243 ± 0.01   | 0.244 ± 0.03    |
| **5th Lumbar µCT**        |                |                 |                |                 |
| Tb.BV/TV (unitless)§      | 0.24 ± 0.09    | 0.08 ± 0.01*    | 0.43 ± 0.05    | 0.40 ± 0.14     |
| Tb.N (1/mm)§              | 4.99 ± 0.5     | 2.09 ± 0.3*     | 6.37 ± 0.7     | 5.29 ± 1.4      |
| Tb.Th (mm)§               | 0.051 ± 0.01   | 0.060 ± 0.01    | 0.072 ± 0.00   | 0.078 ± 0.01    |
| Tb.Sp (mm)§               | 0.190 ± 0.02   | 0.479 ± 0.07*   | 0.141 ± 0.03   | 0.198 ± 0.11    |
| Tb.BMD (mg/cm³)§          | 874.5 ± 14.1   | 871.7 ± 11.3    | 856.4 ± 8.0    | 870.2 ± 17.3    |
| Tb.BMC (mg)†              | 0.40 ± 0.16    | 0.13 ± 0.03*    | 0.58 ± 0.02    | 0.59 ± 0.22     |
| Serum sclerostin (pg/µL)§ | 143.3 ± 37     | 121.6 ± 23*     | 1007 ± 173     | 993.4 ± 109     |

Symbols indicate significance of the main effects and interaction (#=Lrp4 genotype p<0.05; @=Dmp1-hSost p<0.05; †=interaction p<0.05). When at least one term was significant, Fisher’s PLSD post-hoc tests were conducted and are indicated as *p<0.05.
Table S5. Histomorphometric analysis of cortical bone changes and serum sclerostin levels in WT and Lrp4-KI mice treated with sclerostin antibody. Related to Figure 5.

|                        | WT / Veh | WT / Scl-mAb | KI / Veh | KI / Scl-mAb |
|------------------------|----------|--------------|----------|--------------|
| Ec.MS/BS (%)@†         | 70.8±4.0 | 97.9±3.0*    | 82.9±9.2 | 92.1±3.6     |
| Ec.MAR (µm/day)        | 9.16±1.3 | 8.95±0.7     | 10.57±2.3| 9.54±1.7     |
| Ec. BFR/BS (µm³/µm²/yr)| 2381.7±451.8 | 3194.8±225.5 | 3160.3±542.0 | 3192.0±457.0 |
| Serum sclerostin (pg/µL)***† | 207.7±194.4 | 2971.5±44.7* | 780.0±310.2 | 2942.1±45.0* |

Symbols indicate significance of the main effects and interaction (#=Lrp4 genotype p<0.05; @=Scl-mAb p<0.05; †=interaction p<0.05). When at least one term was significant, Fisher’s PLSD post-hoc tests were conducted and are indicated as *p<0.05.
Table S6. Histomorphometric analysis of cortical bone changes from muscle paralysis in WT and Lrp4-KI mice. Related to Figure 6

|                           | WT + Saline | WT + Botox | KI + Saline | KI + Botox |
|---------------------------|-------------|------------|-------------|------------|
| Ps. MS/BS (%) @ | 65.9 ± 25.5 | 13.9 ± 9.6* | 46.9 ± 16.5 | 12.3 ± 4.3* |
| Ps. MAR (µm/day) @      | 0.54 ± 0.17 | 0.0 ± 0.0*  | 0.56 ± 0.16 | 0.30 ± 0.22 |
| Ps. BFR/BS (µm³/µm²/day)@| 134.4 ± 79  | 0.0 ± 0.0*  | 93.1 ± 30   | 15.8 ± 14*  |

Symbols indicate significance of the main effects and interaction (@=Scl-mAb p<0.05). When at least one term was significant, Fisher’s PLSD post-hoc tests were conducted and are indicated as *p<0.05
Transparent Methods

CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Alexander Robling (arobling@iupui.edu).

EXPERIMENTAL MODELS AND SUBJECT DETAILS

Animals

Two different engineered mouse models were used. The first is a new knock-in model of a human patient with an Lrp4 mutation who presented with a sclerosteosis-like phenotype (Leupin et al., 2011). The orthologous mutation was generated in mice using a Crispr/cas9 approach (Fig. 1A). Briefly, a 135bp donor oligo was knocked into the 3’ half of Lrp4 exon 25 and adjacent intron. The donor oligo contained a c.3508C→T mutation (plus several local nonsense mutations to facilitate genotyping) that results in an Arg1170Trp substitution (referred to as Lrp4^{ki}). The second engineered model—^{8kb}Dmp1-hSOST transgenic mice—was utilized to generate overexpression of Sost in bone tissue (Tu et al., 2012). Briefly, a 12-kb DNA fragment containing 8 kb of the 5’-flanking region, the first exon, the first intron, and 17 bp of exon 2 of the murine Dmp1 gene was used to drive expression of a human SOST cDNA. The Dmp1-hSOST mice and Lrp4-R1170W knock-in mice were on a fixed C57Bl/6J background. Male and female mice used in experiments ranged from 4-18 weeks of age. All mice were maintained on-site in accordance with Indiana University IACUC procedures.

METHOD DETAILS

Radiographic imaging

Whole-body DEXA scans were collected on isofluorane-anesthetized mice using a Faxitron UltraFocus^{DXA} x-ray densitometer (Faxitron Bioptics, Inc., Tucson, AZ). All mice were scanned between the ages of 4 to 18 weeks (longitudinal studies) or 3 days prior to the start of the experimental period and again immediately before euthanasia (disuse and antibody studies). From the whole-body scans, areal bone mineral density (BMD) and bone mineral content (BMC) were calculated for the whole body (head and tail excluded) or limbs, depending on the study, using the Faxitron ROI tools.
Collection of serial tibial pQCT measurements in live mice is described elsewhere (Robling et al., 2016). Briefly, a single slice through the proximal tibia, located 4 mm distal to the intracondylar eminence, was collected on isoflurane-anesthetized mice using a Stratec x-ray μScope (Stratec Inc.) at 70-μm resolution. Slices were analyzed for bone mineral content and density using Stratec software in peel mode 2.

After sacrifice, femora or tibiae were scanned, reconstructed, and analyzed on a Scanco μCT-35 desktop microcomputed tomographer (Scanco Medical AG, Brüttisellen Switzerland) as previously described (Niziolek et al., 2015). Briefly, samples were scanned at 10-μm resolution (femur, tibia and vertebra) or 20-μm resolution (skull), 50-kV peak tube potential and 151-ms integration time. Standard output parameters related to cancellous and cortical bone mass, geometry, and architecture were measured and reported (Bouxsein et al., 2010).

Mice received injections of demeclocycline (80 mg/kg), alizarin complexone (20 mg/mL) and calcein (10 mg/kg) at timepoints outlined in individual experiments. After μCT scanning, the fixed femora or tibiae were dehydrated in graded ethanols, cleared in xylene, and embedded in methylmethacrylate. Thick sections were cut from the midshaft using a diamond-embedded wafering saw. Sections were ground and polished to ~30 μm, mounted and coverslipped, then digitally imaged on a fluorescent microscope. Periosteal and endocortical bone formation parameters were calculated by measuring the extent of unlabeled perimeter (nL.Pm), single-labeled perimeter (sL.Pm), double-labeled perimeter (dL.Pm), and the area between the double labeling (dL.Ar) with Image-Pro Plus software (MediaCybernetics Inc., Gaithersburg, MD). The derived histomorphometric parameters mineralizing surface (MS/BS), mineral apposition rate (MAR), and bone formation rate (BFR/BS) were calculated using standard procedures (Dempster et al., 2013).

Molecular Mechanisms

Whole blood samples were collected from wild-type, heterozygous and homozygous Lrp4 mutant mice via cheek bleeding at 8 weeks of age. Approximately 150 μL of blood was collected into serum separator tubes (BD Microtainer), allowed to clot at room temperature for 20 minutes, then centrifuged at 10,000g for 1 minute. Serum was removed and stored at −80°C.
until all samples were collected and assayed together. Serum sclerostin and C-terminal telopeptide were measured by commercially available ELISA kits (Mouse/Rat SOST Quantikine ELISA, R&D Systems; RatLabs CTX-I EIA, iDS) according to the manufacturer's instructions. Serum samples were measured in duplicate and averaged.

In vivo muscle function in Lrp4 mutant mice was evaluated using the 1305A Whole Mouse/Rat Test System (Aurora Scientific Inc., Aurora, ON, Canada) (Organ et al., 2016). Electrodes were inserted subcutaneously near the tibial nerve in anesthetized mice, which were positioned in the instrument to allow ankle dorsiflexion force quantification. Electrode placement and stimulation current were adjusted to achieve the maximum twitch response and then increased to ~35 mA for plantarflexion to ensure supramaximal stimulation of the muscle fibers. The maximum isometric torque (N/m) was recorded for stimulation frequencies between 25 and 300 Hz, with a pulse width of 0.2 ms and strain duration of 200 ms. Data were recorded using the Dynamic Muscle Control/Data Acquisition and Dynamic Muscle Control Data Analysis programs (Aurora Scientific Inc.).

Immediately after sacrifice, mouse femur, tibia and fibula were dissected, stripped of soft tissue, and flushed to remove bone marrow. The remaining cortical bone tissue was immediately snap frozen, pulverized into powder, and solubilized in 800 µL of 4X SDS-PAGE sample buffer. The extract was heated at 95°C for 5 min, centrifuged at 14,000 x g for 10 min, and the supernatant was retained to run directly on gels.

Approximately 20 µg of protein from each sample was run on a 6 % (Lrp4) or 4-12% (sclerostin) polyacrylamide gradient gel (GenScript). Separated proteins were transferred to nitrocellulose overnight, stained with Ponceau-S to visualize total protein and loading consistency. Membranes were blocked in 5% milk, then reacted with primary and HRP-conjugated secondary antibodies. Bound HRP was reacted with ECL reagent (Amersham, ECL Prime Reagent). Blots were imaged using an iBrightCL1000 (Invitrogen).

Eight-week-old female mice (Lrp4+/+ or Lrp4KI/KI) were randomized to receive twice-weekly subcutaneous injections of either sclerostin neutralizing antibody (Scl-mAb) at 25 mg/kg or vehicle control for the next 4 weeks (n = 8 mice per genotype and treatment group). Scl-mAb
doses were adjusted weekly on the basis of body mass measurement. Animals were euthanized by CO2 inhalation when 12 weeks old, followed by tissue harvest.

Parameters related to whole bone strength were measured using 3-point bending tests (Cui et al., 2011). Each femur was loaded to failure in monotonic compression on a TestResources R-series controller, during which force and displacement were collected every 0.01 seconds. From the force/displacement curves, ultimate force and energy to failure were calculated using standard equations (Turner and Burr, 1993).

Forty 12-week-old male mice were used for the Botox experiments, comprising 20 mice of each genotype (i.e., 20 Lrp4KI and 20 wild-type). Each genotype was further divided into control (saline-injected) and Botox-treated mice (n = 10/group). The right hindlimb musculature (quadriceps, triceps surae, tibialis anterior, hamstrings) was injected with a total of 20 μL of Botulinum Toxin A (Botox; Allergan Inc., Irvine, CA), while the left hindlimb musculature was left alone and served as an internal control. Control mice received 20 μL injections of saline in the right hindlimb in an identical fashion as the Botox-treated mice. The injections (both Botox and saline) were repeated one week later to ensure paralysis in the Botox-treated group. Botox efficacy was qualitatively evaluated for each mouse every 3-4 days, based on the inability of the treated mice to use the limb in normal cage locomotion.

DATA AND SOFTWARE AVAILABILITY

Original data can be found at http://dx.doi.org/doi:10.17632/9jm7ftmnsb.1

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical analyses were conducted with SigmaPlot. Statistical details of each experiment can be found in the figure legends. Statistical significance was taken at p<0.05. Two-tailed distributions were used for all analyses. Data are presented as means ± SEM.